DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Ozempic - 1 Roche - 1 Jim Vondruska - 1 Wegovy - 1 ELI LILLY Lilly - 1 Mounjaro - 1 LLY.N - 1
Top related locs:
U.S Hillerod Denmark London Danish Chicago , Illinois Bengaluru
Top related orgs:
Novo Nordisk - 2 pharma - 1 Denmark's Zealand Pharma - 1 U.S . Food - 1 Drug Administration - 1 Zealand Pharma - 1 Nordisk - 1 AstraZeneca - 1

Search resuls for: "Denmark's Zealand Pharma"


2 mentions found


☆ Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
  + stars: | 2024-02-26 | by ( Jenni Reid | ) www.cnbc.com   time to read: +1 min
Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight-loss drug market. The drug has "demonstrated efficacy" in people with obesity and is currently undergoing five Phase-3 trials in a clinical program for people who are overweight or obese. Analysts latched onto the drug's possible efficacity in obesity research following the latest test results, which indicated the safety of the top dosage used in that trial. Several other firms, including Eli Lilly, Roche and AstraZeneca, also seek to compete in the sector.
Persons: Ozempic, Eli Lilly, Roche Organizations: Novo Nordisk, pharma, Denmark's Zealand Pharma, U.S . Food, Drug Administration, Zealand Pharma, Nordisk, AstraZeneca Locations: Hillerod, Denmark, U.S, London, Danish
☆ Factbox: Novo Nordisk's weight-loss drug cuts heart disease risk in study
  + stars: | 2023-05-12 | by ( ) www.reuters.com   time to read: +3 min
[1/2] A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. AMGENAmgen's (AMGN.O) experimental obesity drug, AMG133, showed a mean weight loss of 14.5% after 12 weeks of treatment at the highest monthly dose. The company plans to test higher doses of the drug over a longer treatment window in a mid-stage trial. ZEALAND PHARMADenmark's Zealand Pharma (ZELA.CO) and Boehringer Ingelheim's experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial on Wednesday. OPKO HEALTH Opko Health (OPK.O) has completed a mid-stage trial of its obesity drug, pegapamodutide, which it expects will have fewer side effects.
Persons: Jim Vondruska, Wegovy, Eli Lilly, ELI LILLY Lilly, Mounjaro, LLY.N, danuglipron, AMGEN, ALTIMMUNE, Mariam Sunny, Pratik Jain, Sriparna Roy, Sriraj Kalluvila, Anil D'Silva Organizations: REUTERS, Novo Nordisk, Pfizer, NOVO NORDISK Novo Nordisk, Novo, PFIZER Pfizer Inc, danuglipron, THERAPEUTICS, Therapeutics, ZEALAND PHARMA Denmark's Zealand Pharma, Thomson Locations: Chicago , Illinois, U.S, Bengaluru
0 next >>
Total: 2